Skip to main content

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Publication ,  Journal Article
Davies, MJ; D'Alessio, DA; Fradkin, J; Kernan, WN; Mathieu, C; Mingrone, G; Rossing, P; Tsapas, A; Wexler, DJ; Buse, JB
Published in: Diabetes Care
December 2018

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Diabetes Care

DOI

EISSN

1935-5548

Publication Date

December 2018

Volume

41

Issue

12

Start / End Page

2669 / 2701

Location

United States

Related Subject Headings

  • Weight Loss
  • United States
  • Sodium-Glucose Transporter 2 Inhibitors
  • Obesity
  • Life Style
  • Hypoglycemic Agents
  • Hyperglycemia
  • Humans
  • Europe
  • Endocrinology & Metabolism
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., … Buse, J. B. (2018). Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 41(12), 2669–2701. https://doi.org/10.2337/dci18-0033
Davies, Melanie J., David A. D’Alessio, Judith Fradkin, Walter N. Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J. Wexler, and John B. Buse. “Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetes Care 41, no. 12 (December 2018): 2669–2701. https://doi.org/10.2337/dci18-0033.
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669–701.
Davies, Melanie J., et al. “Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetes Care, vol. 41, no. 12, Dec. 2018, pp. 2669–701. Pubmed, doi:10.2337/dci18-0033.
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669–2701.

Published In

Diabetes Care

DOI

EISSN

1935-5548

Publication Date

December 2018

Volume

41

Issue

12

Start / End Page

2669 / 2701

Location

United States

Related Subject Headings

  • Weight Loss
  • United States
  • Sodium-Glucose Transporter 2 Inhibitors
  • Obesity
  • Life Style
  • Hypoglycemic Agents
  • Hyperglycemia
  • Humans
  • Europe
  • Endocrinology & Metabolism